Doctors prescribed Actos to millions of people with type 2 diabetes to control blood sugar. Although the drug does help with diabetes, studies linked Actos to serious, life-threatening side effects, including heart failure and bladder cancer. The physical, emotional and financial burdens of Actos-related injuries can be costly, and compensation from a lawsuit can help provide relief.
|These lawsuits state that the defendants:|
|Failed to warn the public and health care providers that taking Actos for longer than 12 months may increase the risk of bladder cancer|
|Manufactured a defective product|
|Failed to properly test Actos|
|Concealed testing and research data from the public|
|Provided misleading data to the public|
|Manufactured an unsafe product|
|Knew the dangers of the product, but sold it anyway to maximize profits|
|Breached warranty by selling a drug that was not fit for use|
Some people who file lawsuits do so to punish companies for misleading them and failing to warn the public. These damages are awarded to discourage drug makers from similar conduct.
The cost of treatment can add up – including bills for checkups, surgery, medications, hospital bills, caregiving and funeral expenses.
Inability to work because of medical problems – especially Actos bladder cancer – leads to lost income. Caregivers also lose time from work.
Dealing with Actos health problems, especially those that cause long-term damage, can also cause emotional suffering.
Actos medical issues can also damage the relationship between spouses.
Each year in the United States, about 70,000 people are diagnosed with bladder cancer. If caught before it spreads, the cancer can usually be treated. However, it has a high recurrence rate. Takeda does not acknowledge any links between Actos and bladder cancer.
The FDA considers the risk of congestive heart failure from Actos to be significant enough to require a black-box warning on the drug's label. Avandia, another drug in the same class, is also known to cause severe heart problems.
Takeda and Eli Lilly launched Actos, a thiazolidinedione (TZD). Pre-approval studies showed tumors in rats given the drug. Its label said the relationship between the tumors in rats and possible tumors in humans is "unclear."
Two clinical studies that were a part of Takeda's PROactive study revealed a higher percentage of bladder cancer in people taking Actos as opposed to another drug.
Eli Lilly stops marketing Actos. The drug's label is changed to add the findings from a two-year study that showed bladder tumors in rats given a high dose of Actos.
FDA begins reviewing data from 10 year Actos study
French study finds increased bladder cancer risk in patients taking Actos. The drug is pulled off market in France, and Germany recommended not starting Actos in new patients.
FDA releases safety announcement warning that using Actos for over a year "may be associated with an increased risk of bladder cancer."
First Actos bladder cancer suits are filed.
Louisiana resident Darin Andrews filed a lawsuit against Takeda in 2012 after being diagnosed with bladder cancer several months after he started taking Actos. His lawsuit states the drug was "inadequately tested, dangerous to human health and lacked proper warnings."
Edwene Person's husband, James, was diagnosed with and died from bladder cancer after taking Actos. Her lawsuit states that James' injuries were a result of the defendants' "wrongful conduct, acts, omissions, [and] fraudulent misrepresentations."
In 2013, a jury awarded Jack Cooper $6.5M in damages after he took Actos and was diagnosed with bladder cancer. Takeda was found guilty of failure to warn but convinced the judge a witness was unreliable and the verdict was overturned. Cooper's attorneys are appealing.